bluebird bio (BLUE) Misses Q4 EPS by 18c

bluebird bio (NASDAQ: BLUE) reported Q4 EPS of ($1.29), $0.18 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $1.47 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• UBS Downgrades Mondi PLC (MNDI:LN) (MONDY) to Neutral
• AeroVironment posts record quarterly revenue, issues FY2027 outlook